RT @ESCAdvocacy: A major setback for cardiovascular care with no new medicines approved in 2022, according to @EMA_News. @escardio calls on policymakers to prioritize #CardiovascularHealth and support the development of new #therapies that make a difference for #patients. https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2022_en.pdf

🐦🔗: https://n.respublicae.eu/mgracacarvalho/status/1626545206962139137